Finding and validating new targets for T-LBLL targeted immunotherapy

With surface protein identification, using LC/MS2, we will try to identify antigens more prevalent on T cell acute lymphoblastic leukemia/ lymphoma. This is to generate novel chimeric antigen receptors that are needed by the refractory patient group.

Contact 
Dani Holla